Coherus Bio (CHRS)

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Aug 19, 2021

Good morning, trader! We're back at it once again with another update on the biggest pre-market stock movers for Thursday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jun 4, 2021

InvestorPlace is kicking off Friday with a look at the biggest pre-market stock movers for the day as we prepare for that weekend break.

Trade of the Day: Coherus Biosciences Inc (CHRS)

By Ken Trester Nov 17, 2017

While generally speaking I like biotech, in a weakening market it's a good idea to trade neglected and unloved names to the downside.

Why Coherus Biosciences Stock Tumbled on Thursday

From The Motley Fool Mar 14, 2024

The company fell well short of expectations for its fourth quarter.

Why Coherus BioSciences Stock Jumped Today

From The Motley Fool Feb 6, 2024

As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.

Why Coherus BioSciences Stock Is Sinking Today

From The Motley Fool Jan 23, 2024

The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.

Why Coherus Biosciences Popped Today

From The Motley Fool Jan 22, 2024

Coherus is divesting its non-core ophthalmology franchise.

Coherus (NASDAQ:CHRS) Surges After $170M Deal with Sandoz for CIMERLI Franchise

From TipRanks Jan 22, 2024

Commercial-stage biopharmaceutical company Coherus BioSciences (NASDAQ: CHRS) surged in pre-market trading after the company announced that it will divest its ophth...

Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal

From Seeking Alpha Jan 22, 2024

Sandoz (SDZNY) has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI from Coherus BioSciences (CHRS) for an upfront cash purchase payment of $170 million, along with an..

Coherus Bio (CHRS)

CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024

Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Coherus Bio (CHRS)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CHRS Stock Predictions, Articles, and Coherus Bio News

Subscriber Sign in